Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Tipo de documento: | Tese |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações da UERJ |
Texto Completo: | http://www.bdtd.uerj.br/handle/1/12665 |
Resumo: | Insulin resistance (IR) is associated with intramyocellular lipid (IMCL) content and low serum adiponectin (ADP) levels. ADP is also involved in muscle fat oxidation but the relationship between them is still controversial. We aimed to further explore the relationship between ADP and IMCL content in non-diabetic adults and the role of rosiglitazone (RSG) in muscle fat compartment distribution in an adult population of obese nondiabetic metabolic syndrome patients. This study comprises two phases: a cross-sectional and a longitudinal, open-label, drug-interventional one. Laboratory for Clinical and Experimental Research on Vascular Biology (Biovasc) at the State University of Rio de Janeiro. During the cross-sectional phase, 24 obese, nondiabetic patients with metabolic syndrome (MS) and 9 lean healthy controls were studied. Proton nuclear magnetic resonance spectroscopy (1H-NMRS) was performed to quantify IMCL, as well as extramyocellular lipid (EMCL) content. The latter plus serum ADP, anthropometrics and biochemical parameters were evaluated and compared in these two groups. During the longitudinal phase, fifteen of the MS patients were studied by means of 1HNMRS before and after treatment with 8mg/day of RSG for 6 months. Anthropometrical and metabolic variables were assessed. Measurements and main results cross-sectional phase: MS patients had higher body mass index (BMI), waist, waist-to-hip ratio (WHR), glucose, insulin and triglycerides and lower HDL-c as compared to controls. HOMA-IR (3.25 [2.58-4.13] vs 1.02 [0.73-1.29]; p<0.0001) and IMCL content (266.1 [189.9-296.3] vs 72.85 [55.3-109.4) AU, p<0.0001] were higher, and QUICKI (0.32 [0.31-0.33] vs 0.38 [0.37-0.40]; p<0.0001) and ADP (8.6 [4.05-15.95] vs 21.1 [12.9-24.4] μg/ml; p=0.02) lower in MS compared to controls. IMCL content was directly associated with glucose, insulin, triglycerides and HOMAxiii IR and inversely to HDLc, QUICKI and, more importantly, with ADP (r = -0.41; p<0.05). Longitudinal phase: After RSG treatment, body weight and hip circumference increased [100.9 (91.12-138.7) vs 107,0 (79.6-142.8) kg and 118 (107-126) cm vs 122 (110-131) cm] respectively, while WHR decreased [0.93 (0.87-1.00) vs 0.89 (0.82-0.97); P<0.001 for all]. Additionally, fasting plasma glucose, insulin and HOMA-IR significantly decreased while adiponectin increased over 3 fold [9.7 (3.7-17.7) vs 38.0 (19.3-42.4) μg/ml]. Finally, IMCL did not change [267.54 (213.94-297.94) vs 305.75 (230.80-424.75) arbitrary units (AU)] while EMCL increased [275.53 (210.39-436.66) vs 411.39 (279.92-556.59) AU; P<0.01] therefore decreasing IMCL to EMCL ratio (IMCL/EMCL) [1.07 (0.78-1.23) vs. 0.71 (0.53-0.96); p<0.01]. ADP is inversely related to IMCL content in non-diabetic adults. This finding has possible implications for the role of ADP in muscle fat oxidation, IR and MS. RSG treatment increased body weight and hip circumference decreasing WHR and decreased IMCL/EMCL ratio by increasing EMCL without any significant change on IMCL, thus suggesting that this drug may prevent IMCL fat deposition by increasing EMCL and peripheral deposits. |
id |
UERJ_908729a201a584a521828128faea74fe |
---|---|
oai_identifier_str |
oai:www.bdtd.uerj.br:1/12665 |
network_acronym_str |
UERJ |
network_name_str |
Biblioteca Digital de Teses e Dissertações da UERJ |
repository_id_str |
2903 |
spelling |
Bouskela, Elietehttp://lattes.cnpq.br/7142823902123714Aguiar, Luiz Guilherme Kraemer dehttp://lattes.cnpq.br/8595649779399114Póvoa, Luiz Césarhttp://lattes.cnpq.br/3701711248055310Silva, Patrícia Cristina Lisbôa dahttp://lattes.cnpq.br/6704904748735082Halpern, Alfredohttp://lattes.cnpq.br/1620596652889285Oliveira, Jose Egidio Paulo dehttp://lattes.cnpq.br/3849823811830848http://lattes.cnpq.br/4850752035210309Matos, Amélio Fernando de Godoy2021-01-06T20:54:13Z2010-06-162009-08-18MATOS, Amélio Fernando de Godoy. Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona. 2009. 136 f. Tese (Doutorado em Fisiopatologia Clínica e Experimental) - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2009.http://www.bdtd.uerj.br/handle/1/12665Insulin resistance (IR) is associated with intramyocellular lipid (IMCL) content and low serum adiponectin (ADP) levels. ADP is also involved in muscle fat oxidation but the relationship between them is still controversial. We aimed to further explore the relationship between ADP and IMCL content in non-diabetic adults and the role of rosiglitazone (RSG) in muscle fat compartment distribution in an adult population of obese nondiabetic metabolic syndrome patients. This study comprises two phases: a cross-sectional and a longitudinal, open-label, drug-interventional one. Laboratory for Clinical and Experimental Research on Vascular Biology (Biovasc) at the State University of Rio de Janeiro. During the cross-sectional phase, 24 obese, nondiabetic patients with metabolic syndrome (MS) and 9 lean healthy controls were studied. Proton nuclear magnetic resonance spectroscopy (1H-NMRS) was performed to quantify IMCL, as well as extramyocellular lipid (EMCL) content. The latter plus serum ADP, anthropometrics and biochemical parameters were evaluated and compared in these two groups. During the longitudinal phase, fifteen of the MS patients were studied by means of 1HNMRS before and after treatment with 8mg/day of RSG for 6 months. Anthropometrical and metabolic variables were assessed. Measurements and main results cross-sectional phase: MS patients had higher body mass index (BMI), waist, waist-to-hip ratio (WHR), glucose, insulin and triglycerides and lower HDL-c as compared to controls. HOMA-IR (3.25 [2.58-4.13] vs 1.02 [0.73-1.29]; p<0.0001) and IMCL content (266.1 [189.9-296.3] vs 72.85 [55.3-109.4) AU, p<0.0001] were higher, and QUICKI (0.32 [0.31-0.33] vs 0.38 [0.37-0.40]; p<0.0001) and ADP (8.6 [4.05-15.95] vs 21.1 [12.9-24.4] μg/ml; p=0.02) lower in MS compared to controls. IMCL content was directly associated with glucose, insulin, triglycerides and HOMAxiii IR and inversely to HDLc, QUICKI and, more importantly, with ADP (r = -0.41; p<0.05). Longitudinal phase: After RSG treatment, body weight and hip circumference increased [100.9 (91.12-138.7) vs 107,0 (79.6-142.8) kg and 118 (107-126) cm vs 122 (110-131) cm] respectively, while WHR decreased [0.93 (0.87-1.00) vs 0.89 (0.82-0.97); P<0.001 for all]. Additionally, fasting plasma glucose, insulin and HOMA-IR significantly decreased while adiponectin increased over 3 fold [9.7 (3.7-17.7) vs 38.0 (19.3-42.4) μg/ml]. Finally, IMCL did not change [267.54 (213.94-297.94) vs 305.75 (230.80-424.75) arbitrary units (AU)] while EMCL increased [275.53 (210.39-436.66) vs 411.39 (279.92-556.59) AU; P<0.01] therefore decreasing IMCL to EMCL ratio (IMCL/EMCL) [1.07 (0.78-1.23) vs. 0.71 (0.53-0.96); p<0.01]. ADP is inversely related to IMCL content in non-diabetic adults. This finding has possible implications for the role of ADP in muscle fat oxidation, IR and MS. RSG treatment increased body weight and hip circumference decreasing WHR and decreased IMCL/EMCL ratio by increasing EMCL without any significant change on IMCL, thus suggesting that this drug may prevent IMCL fat deposition by increasing EMCL and peripheral deposits.A resistência à insulina está associada com o aumento do teor de gordura intramiocelular (GIMC) e com níveis séricos da adiponectina (ADP) diminuídos. A ADP por sua vez está envolvida na oxidação de gordura muscular. Entretanto, a relação entre ambas continua controversa. O objetivo deste estudo é explorar a relação entre a ADP e a GIMC em adultos não diabéticos, além de estudar o papel da rosiglitasona (RSG) sobre a distribuição da gordura entre os compartimentos musculares. Este estudo compreende duas fases: uma fase transversal (corte-transversal) e uma fase longitudinal, de intervenção terapêutica com uma droga, num desenho aberto. Laboratório de Pesquisas Clínicas e Experimentais em Biologia Vascular (Biovasc) - UERJ. Material e métodos Na fase transversal, 24 pacientes obesos, não diabéticos, com síndrome metabólica (SM) e 9 controles magros e saudáveis foram estudados. Foi realizada a Espectroscopia de Prótons por Ressonância Nuclear Magnética (1H-ERNM) para quantificar a gordura extramiocelular (GEMC) e a GIMC. Estas, associadas à ADP e aos parâmetros antropométricos e bioquímicos, foram avaliadas e comparadas nos dois grupos. Durante a fase longitudinal, 15 destes pacientes foram reestudados, através da 1H-ERNM, após o tratamento com RSG por 6 meses. Da mesma forma, as variáveis antropométricas e metabólicas foram reavaliadas. Fase transversal: os pacientes com SM apresentaram maior índice de massa corporal (IMC), cintura abdominal, relação cintura-quadril (RCQ), e níveis de glicemia, insulina e triglicerídeos e menores níveis de HDL-c, quando comparados com o grupo controle. Da mesma forma o HOMA-RI [3.25 (2.58-4.13) vs 1.02 (0.73-1.29); p<0.0001] e a GIMC [266.1 (189.9-296.3) vs 72.85 (55.3-109.4) unidades arbitrárias-UA, p<0.0001] estavam aumentados enquanto o QUICKI [0.32 (0.31-0.33) vs 0.38 (0.37-0.40); p<0.0001] e a ADP [8.6 (4.05-15.95) vs 21.1 (12.9-24.4) μg/ml; p=0.02) estavam diminuídos. O teor de GIMC associou-se diretamente com a glicose, insulina, triglicerídeos e HOMA-RI e inversamente com o HDL-c, QUICKI e, mais importantemente, com a ADP (r = -0.41; p<0.05). Fase longitudinal: após o tratamento com RSG, o peso corporal e a circunferência do quadril aumentaram, respectivamente [100.9 (91.12-138.7) vs 107,0 (79.6-142.8) kg e 118 (107-126) cm vs 122 (110-131) cm]; enquanto a RCQ diminuiu [0.93 (0.87-1.00) vs 0.89 (0.82-0.97); P<0.001 para todos]. Adicionalmente, a glicemia, a insulina e o HOMA-RI diminuíram significativamente, enquanto a ADP aumentou mais de 3 vezes [9.7 (3.7-17.7) vs 38.0 (19.3-42.4) μg/ml]. Finalmente, a GIMC não se modificou [267.54 (213.94-297.94) vs 305.75 (230.80-424.75) UA], mas a GEMC aumentou de forma significativa [275.53 (210.39-436.66) vs 411.39 (279.92-556.59) UA; P<0.01] diminuindo a razão GIMC sobre GEMC [GIMC/GEMC; 1.07 (0.78-1.23) vs. 0.71 (0.53-0.96); p<0.01]. A ADP correlacionou-se inversamente com o teor da GIMC em adultos obesos não diabéticos com SM. Este achado tem possíveis implicações para o papel da ADP na oxidação da gordura muscular, na RI e na SM. O tratamento com RSG aumentou a massa corporal e a circunferência do quadril e diminuiu a RCQ. Além disso, diminuiu a razão GIMC/GEMC, por aumentar a GEMC sem alterar significativamente a GIMC. Isto sugere que este medicamento pode prevenir a deposição da gordura no compartimento intramiocelular ao aumentar os depósitos periféricos e o extramiocelular.Submitted by Boris Flegr (boris@uerj.br) on 2021-01-06T20:54:13Z No. of bitstreams: 1 Amelio Fernando Godoy de Matos Completa.pdf: 734273 bytes, checksum: f20e7e27d9b9cc36e2f224aed5afa8e0 (MD5)Made available in DSpace on 2021-01-06T20:54:13Z (GMT). No. of bitstreams: 1 Amelio Fernando Godoy de Matos Completa.pdf: 734273 bytes, checksum: f20e7e27d9b9cc36e2f224aed5afa8e0 (MD5) Previous issue date: 2009-08-18application/pdfporUniversidade do Estado do Rio de JaneiroPrograma de Pós-Graduação em Fisiopatologia Clínica e ExperimentalUERJBRCentro Biomédico::Faculdade de Ciências MédicasAdiponectinIntramyocellular fatMetabolic SyndromeRosiglitazoneAdiponectinaGordura intramiocelularSíndrome metabólicaRosiglitazonaCNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::ENDOCRINOLOGIARelação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da RosiglitazonaRelationship between the Metabolic Syndrome, intramyocellular fat and plasma Adiponectin: role of Rosiglitazoneinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UERJinstname:Universidade do Estado do Rio de Janeiro (UERJ)instacron:UERJORIGINALAmelio Fernando Godoy de Matos Completa.pdfapplication/pdf734273http://www.bdtd.uerj.br/bitstream/1/12665/1/Amelio+Fernando+Godoy+de+Matos+Completa.pdff20e7e27d9b9cc36e2f224aed5afa8e0MD511/126652024-02-26 16:36:39.623oai:www.bdtd.uerj.br:1/12665Biblioteca Digital de Teses e Dissertaçõeshttp://www.bdtd.uerj.br/PUBhttps://www.bdtd.uerj.br:8443/oai/requestbdtd.suporte@uerj.bropendoar:29032024-02-26T19:36:39Biblioteca Digital de Teses e Dissertações da UERJ - Universidade do Estado do Rio de Janeiro (UERJ)false |
dc.title.por.fl_str_mv |
Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona |
dc.title.alternative.eng.fl_str_mv |
Relationship between the Metabolic Syndrome, intramyocellular fat and plasma Adiponectin: role of Rosiglitazone |
title |
Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona |
spellingShingle |
Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona Matos, Amélio Fernando de Godoy Adiponectin Intramyocellular fat Metabolic Syndrome Rosiglitazone Adiponectina Gordura intramiocelular Síndrome metabólica Rosiglitazona CNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::ENDOCRINOLOGIA |
title_short |
Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona |
title_full |
Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona |
title_fullStr |
Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona |
title_full_unstemmed |
Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona |
title_sort |
Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona |
author |
Matos, Amélio Fernando de Godoy |
author_facet |
Matos, Amélio Fernando de Godoy |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Bouskela, Eliete |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/7142823902123714 |
dc.contributor.advisor-co1.fl_str_mv |
Aguiar, Luiz Guilherme Kraemer de |
dc.contributor.advisor-co1Lattes.fl_str_mv |
http://lattes.cnpq.br/8595649779399114 |
dc.contributor.referee1.fl_str_mv |
Póvoa, Luiz César |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/3701711248055310 |
dc.contributor.referee2.fl_str_mv |
Silva, Patrícia Cristina Lisbôa da |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/6704904748735082 |
dc.contributor.referee3.fl_str_mv |
Halpern, Alfredo |
dc.contributor.referee3Lattes.fl_str_mv |
http://lattes.cnpq.br/1620596652889285 |
dc.contributor.referee4.fl_str_mv |
Oliveira, Jose Egidio Paulo de |
dc.contributor.referee4Lattes.fl_str_mv |
http://lattes.cnpq.br/3849823811830848 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/4850752035210309 |
dc.contributor.author.fl_str_mv |
Matos, Amélio Fernando de Godoy |
contributor_str_mv |
Bouskela, Eliete Aguiar, Luiz Guilherme Kraemer de Póvoa, Luiz César Silva, Patrícia Cristina Lisbôa da Halpern, Alfredo Oliveira, Jose Egidio Paulo de |
dc.subject.eng.fl_str_mv |
Adiponectin Intramyocellular fat Metabolic Syndrome Rosiglitazone |
topic |
Adiponectin Intramyocellular fat Metabolic Syndrome Rosiglitazone Adiponectina Gordura intramiocelular Síndrome metabólica Rosiglitazona CNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::ENDOCRINOLOGIA |
dc.subject.por.fl_str_mv |
Adiponectina Gordura intramiocelular Síndrome metabólica Rosiglitazona |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::ENDOCRINOLOGIA |
description |
Insulin resistance (IR) is associated with intramyocellular lipid (IMCL) content and low serum adiponectin (ADP) levels. ADP is also involved in muscle fat oxidation but the relationship between them is still controversial. We aimed to further explore the relationship between ADP and IMCL content in non-diabetic adults and the role of rosiglitazone (RSG) in muscle fat compartment distribution in an adult population of obese nondiabetic metabolic syndrome patients. This study comprises two phases: a cross-sectional and a longitudinal, open-label, drug-interventional one. Laboratory for Clinical and Experimental Research on Vascular Biology (Biovasc) at the State University of Rio de Janeiro. During the cross-sectional phase, 24 obese, nondiabetic patients with metabolic syndrome (MS) and 9 lean healthy controls were studied. Proton nuclear magnetic resonance spectroscopy (1H-NMRS) was performed to quantify IMCL, as well as extramyocellular lipid (EMCL) content. The latter plus serum ADP, anthropometrics and biochemical parameters were evaluated and compared in these two groups. During the longitudinal phase, fifteen of the MS patients were studied by means of 1HNMRS before and after treatment with 8mg/day of RSG for 6 months. Anthropometrical and metabolic variables were assessed. Measurements and main results cross-sectional phase: MS patients had higher body mass index (BMI), waist, waist-to-hip ratio (WHR), glucose, insulin and triglycerides and lower HDL-c as compared to controls. HOMA-IR (3.25 [2.58-4.13] vs 1.02 [0.73-1.29]; p<0.0001) and IMCL content (266.1 [189.9-296.3] vs 72.85 [55.3-109.4) AU, p<0.0001] were higher, and QUICKI (0.32 [0.31-0.33] vs 0.38 [0.37-0.40]; p<0.0001) and ADP (8.6 [4.05-15.95] vs 21.1 [12.9-24.4] μg/ml; p=0.02) lower in MS compared to controls. IMCL content was directly associated with glucose, insulin, triglycerides and HOMAxiii IR and inversely to HDLc, QUICKI and, more importantly, with ADP (r = -0.41; p<0.05). Longitudinal phase: After RSG treatment, body weight and hip circumference increased [100.9 (91.12-138.7) vs 107,0 (79.6-142.8) kg and 118 (107-126) cm vs 122 (110-131) cm] respectively, while WHR decreased [0.93 (0.87-1.00) vs 0.89 (0.82-0.97); P<0.001 for all]. Additionally, fasting plasma glucose, insulin and HOMA-IR significantly decreased while adiponectin increased over 3 fold [9.7 (3.7-17.7) vs 38.0 (19.3-42.4) μg/ml]. Finally, IMCL did not change [267.54 (213.94-297.94) vs 305.75 (230.80-424.75) arbitrary units (AU)] while EMCL increased [275.53 (210.39-436.66) vs 411.39 (279.92-556.59) AU; P<0.01] therefore decreasing IMCL to EMCL ratio (IMCL/EMCL) [1.07 (0.78-1.23) vs. 0.71 (0.53-0.96); p<0.01]. ADP is inversely related to IMCL content in non-diabetic adults. This finding has possible implications for the role of ADP in muscle fat oxidation, IR and MS. RSG treatment increased body weight and hip circumference decreasing WHR and decreased IMCL/EMCL ratio by increasing EMCL without any significant change on IMCL, thus suggesting that this drug may prevent IMCL fat deposition by increasing EMCL and peripheral deposits. |
publishDate |
2009 |
dc.date.issued.fl_str_mv |
2009-08-18 |
dc.date.available.fl_str_mv |
2010-06-16 |
dc.date.accessioned.fl_str_mv |
2021-01-06T20:54:13Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
format |
doctoralThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
MATOS, Amélio Fernando de Godoy. Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona. 2009. 136 f. Tese (Doutorado em Fisiopatologia Clínica e Experimental) - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2009. |
dc.identifier.uri.fl_str_mv |
http://www.bdtd.uerj.br/handle/1/12665 |
identifier_str_mv |
MATOS, Amélio Fernando de Godoy. Relação entre a Síndrome Metabólica, teor de gordura intramiocelular e os níveis plasmáticos da Adiponectina: papel da Rosiglitazona. 2009. 136 f. Tese (Doutorado em Fisiopatologia Clínica e Experimental) - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2009. |
url |
http://www.bdtd.uerj.br/handle/1/12665 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade do Estado do Rio de Janeiro |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Fisiopatologia Clínica e Experimental |
dc.publisher.initials.fl_str_mv |
UERJ |
dc.publisher.country.fl_str_mv |
BR |
dc.publisher.department.fl_str_mv |
Centro Biomédico::Faculdade de Ciências Médicas |
publisher.none.fl_str_mv |
Universidade do Estado do Rio de Janeiro |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UERJ instname:Universidade do Estado do Rio de Janeiro (UERJ) instacron:UERJ |
instname_str |
Universidade do Estado do Rio de Janeiro (UERJ) |
instacron_str |
UERJ |
institution |
UERJ |
reponame_str |
Biblioteca Digital de Teses e Dissertações da UERJ |
collection |
Biblioteca Digital de Teses e Dissertações da UERJ |
bitstream.url.fl_str_mv |
http://www.bdtd.uerj.br/bitstream/1/12665/1/Amelio+Fernando+Godoy+de+Matos+Completa.pdf |
bitstream.checksum.fl_str_mv |
f20e7e27d9b9cc36e2f224aed5afa8e0 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações da UERJ - Universidade do Estado do Rio de Janeiro (UERJ) |
repository.mail.fl_str_mv |
bdtd.suporte@uerj.br |
_version_ |
1792352316109619200 |